Biotech Production Plant Biogen Plans new Manufacturing Plant in Switzerland, Appoints Jacobs

Editor: Dominik Stephan

Jacobs Engineering of California will provide engineering, procurement and construction management (EPCM) services for Biogen’s new biotech production plant in Luterbach, Switzerland.

Related Vendors

Jacobs wins a new EPCM contract with Biogen in Switzerland.
Jacobs wins a new EPCM contract with Biogen in Switzerland.
(Picture: Ernhofer/PROCESS)

Cambridge, Massachusetts/USA –Biogen plans a new state-of-the-art biotech manufacturing plant in Switzerland which shall commence operation by 2021. The American company has now signed an agreement with Jacobs covering the EPCM services for the proposed production site, which is expected to triple the company’s global capacity to produce large protein-based drugs known as biologics. Work on the facility was expected to begin in late 2015.

“We are pleased Biogen chose to work with us to meet its demands for increased manufacturing capacity. As the largest professional services provider to the biopharmaceutical industry, we look forward to providing innovative solutions that can help strengthen its medication supply system around the globe” explained Jacobs Global Life Sciences Senior Vice President Robert Norfleet. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological, autoimmune and rare diseases. The company currently manufactures therapies in Cambridge, Massachusetts; Research Triangle Park, North Carolina; and Hillerød, Denmark.